In the association between hypercholesterolemia (HC) and thrombotic risk platelet hyper-reactivity plays an important role. The inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) to reduce plasma LDL-cholesterol merges as effective therapeutic strategy to prevent cardiovascular (CV) events. Aim of this study was to verify whether a treatment up to 12 months with the monoclonal antibodies (mAbs) anti-PCSK9 influences platelet function in primary HC.
Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up
Barale C.First
;Bonomo K.;Frascaroli C.;Morotti A.;Guerrasio A.;Russo I.
Last
2020-01-01
Abstract
In the association between hypercholesterolemia (HC) and thrombotic risk platelet hyper-reactivity plays an important role. The inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) to reduce plasma LDL-cholesterol merges as effective therapeutic strategy to prevent cardiovascular (CV) events. Aim of this study was to verify whether a treatment up to 12 months with the monoclonal antibodies (mAbs) anti-PCSK9 influences platelet function in primary HC.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0939475319303515-main-1.pdf
Accesso riservato
Descrizione: Articolo Principale
Tipo di file:
PDF EDITORIALE
Dimensione
768.06 kB
Formato
Adobe PDF
|
768.06 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Guerrasio_3_Platelet function.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
783.66 kB
Formato
Adobe PDF
|
783.66 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Barale et al NMCD 2019 (2).pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
531.94 kB
Formato
Adobe PDF
|
531.94 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
